Hospital
Kaiser Foundation Hospitals
Kaiser Foundation Hospitals was paid $66.22M by Medicaid between Jan 2018 and Dec 2024, across 352 billing codes. Its largest line is 99283, emergency room visit (moderate) — 28% of everything it billed.
33Billing provider infoKAISER FOUNDATION HOSPITALS
LOS ANGELES, CA 90027
LOS ANGELES, CA 90027
33aNPI1821143777assigned 01/23/2007
33bProvider typeGeneral Acute Care Hospital
28Total paid$66.22M
24GClaims2,019,246
24DCodes billed352
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#41 of 410
Median peer was paid$6.90M
This provider vs. median9.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 190,819 | $759K | |
| 2019 | 284,863 | $8.72M | |
| 2020 | 255,776 | $14.12M | |
| 2021 | 274,857 | $9.66M | |
| 2022 | 291,094 | $10.82M | |
| 2023 | 340,914 | $10.10M | |
| 2024incomplete | 380,923 | $12.04M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 28% | 41,813 | 38,492 | $18.28M |
| G0378 | Hospital observation service, per hour | 14% | 7,563 | 4,670 | $9.04M |
| 93458 | 8.1% | 1,055 | 1,050 | $5.34M | |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 6.4% | 5,272 | 5,110 | $4.26M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.5% | 5,413 | 5,306 | $1.68M |
| 0450 | Emergency room services | 2.5% | 36,870 | 32,245 | $1.65M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.9% | 6,533 | 6,314 | $1.26M |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | 1.2% | 359 | 355 | $811K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 1.2% | 17,184 | 16,580 | $790K |
| 82565 | 1.1% | 148,830 | 130,838 | $714K | |
| 70450 | Computed tomography, head or brain; without contrast material | 1.0% | 6,611 | 6,455 | $678K |
| 80051 | 1.0% | 121,542 | 105,202 | $673K |
340 more codes
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,580 | $619K |
| 80061 | Lipid panel | <1% | 40,045 | $565K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 56,207 | $558K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 32,784 | $550K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 3,125 | $544K |
| 86900 | <1% | 9,085 | $533K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 91,953 | $524K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 15,953 | $523K |
| 84460 | <1% | 93,315 | $488K | |
| 86885 | <1% | 6,356 | $470K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 12,899 | $460K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 12,895 | $460K |
| 71045 | Radiologic examination, chest; single view | <1% | 9,634 | $456K |
| 85027 | <1% | 74,299 | $437K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 226 | $421K |
| 83880 | <1% | 13,969 | $389K | |
| 85097 | <1% | 543 | $383K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,117 | $323K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 5,862 | $269K |
| 72197 | <1% | 623 | $266K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,144 | $266K |
| 87536 | <1% | 3,094 | $265K | |
| 83970 | <1% | 5,735 | $265K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 204 | $262K |
| 74183 | <1% | 605 | $252K | |
| 82247 | <1% | 50,387 | $227K | |
| 84075 | <1% | 47,695 | $225K | |
| 84450 | <1% | 46,528 | $218K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,818 | $214K |
| 62323 | <1% | 396 | $212K | |
| 93971 | <1% | 1,041 | $209K | |
| 76830 | Ultrasound, transvaginal | <1% | 2,721 | $208K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,425 | $204K |
| 84520 | <1% | 76,131 | $204K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 4,614 | $189K |
| 88184 | <1% | 692 | $185K | |
| 82728 | <1% | 12,780 | $181K | |
| 86923 | <1% | 857 | $180K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 8,034 | $178K |
| 86141 | <1% | 13,024 | $170K | |
| 86901 | <1% | 9,095 | $164K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 3,933 | $162K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 8,849 | $162K |
| 82310 | <1% | 31,864 | $156K | |
| 82947 | <1% | 61,066 | $149K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 625 | $139K |
| 86780 | <1% | 10,296 | $136K | |
| 86480 | <1% | 1,924 | $123K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 4,158 | $122K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 531 | $121K |
| 82607 | <1% | 7,654 | $121K | |
| 86803 | <1% | 8,696 | $120K | |
| 87505 | <1% | 1,118 | $118K | |
| 83550 | <1% | 13,007 | $114K | |
| 82043 | <1% | 17,320 | $114K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 1,221 | $114K |
| 84702 | <1% | 10,913 | $113K | |
| 83735 | <1% | 22,167 | $110K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 424 | $105K |
| 85610 | <1% | 31,022 | $102K | |
| 73562 | <1% | 1,922 | $102K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 8,604 | $100K |
| 77080 | <1% | 615 | $100K | |
| 82040 | <1% | 19,872 | $97K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,328 | $95K |
| 81003 | <1% | 52,176 | $94K | |
| 73630 | <1% | 1,756 | $90K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,326 | $89K |
| 73030 | <1% | 1,487 | $88K | |
| 0637 | <1% | 76,752 | $82K | |
| 83540 | <1% | 12,946 | $81K | |
| 83520 | <1% | 4,294 | $78K | |
| 78451 | <1% | 55 | $76K | |
| 99199 | Unlisted special service, procedure or report | <1% | 2,080 | $76K |
| 84153 | <1% | 3,984 | $75K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 5,585 | $75K |
| 84484 | <1% | 17,334 | $71K | |
| 72100 | <1% | 859 | $70K | |
| 83721 | <1% | 6,250 | $69K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 23,801 | $69K |
| 83690 | <1% | 18,088 | $68K | |
| 73610 | <1% | 1,469 | $64K | |
| 87088 | <1% | 12,431 | $63K | |
| 87340 | <1% | 6,489 | $62K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 309 | $61K |
| 74018 | <1% | 1,148 | $61K | |
| 0250 | <1% | 12,413 | $58K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 628 | $58K |
| 82570 | <1% | 9,501 | $57K | |
| 90686 | <1% | 3,838 | $57K | |
| 84100 | <1% | 15,503 | $54K | |
| 83655 | <1% | 5,059 | $53K | |
| 82746 | <1% | 3,426 | $51K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,589 | $50K |
| 84403 | <1% | 1,828 | $47K | |
| 93970 | <1% | 141 | $45K | |
| 71250 | <1% | 340 | $43K | |
| 81513 | <1% | 579 | $43K | |
| 76770 | <1% | 332 | $42K | |
| Z7502 | <1% | 1,291 | $41K | |
| 85652 | <1% | 15,072 | $40K | |
| 73130 | <1% | 920 | $40K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 370 | $39K |
| 72141 | <1% | 165 | $39K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 215 | $39K |
| 70496 | <1% | 161 | $37K | |
| 84156 | <1% | 8,738 | $37K | |
| 86762 | <1% | 2,606 | $36K | |
| 80076 | <1% | 4,669 | $35K | |
| 82378 | <1% | 1,629 | $35K | |
| 84165 | <1% | 2,827 | $35K | |
| 73564 | <1% | 250 | $35K | |
| 86787 | <1% | 2,813 | $33K | |
| 82248 | <1% | 9,047 | $31K | |
| 84439 | <1% | 3,565 | $31K | |
| 80197 | <1% | 2,011 | $30K | |
| 82105 | <1% | 1,694 | $30K | |
| 73110 | <1% | 545 | $30K | |
| 83718 | <1% | 3,763 | $29K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 8,735 | $29K |
| 88342 | <1% | 189 | $29K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 2,108 | $27K |
| 73502 | <1% | 382 | $27K | |
| 82784 | <1% | 1,306 | $27K | |
| 70498 | <1% | 113 | $27K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 2,010 | $26K |
| 76536 | <1% | 193 | $26K | |
| 86317 | <1% | 1,833 | $25K | |
| 76641 | <1% | 215 | $25K | |
| 80306 | <1% | 2,497 | $25K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,974 | $25K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,190 | $24K |
| 87497 | <1% | 469 | $24K | |
| J3490 | Unclassified drugs | <1% | 5,386 | $24K |
| 86038 | <1% | 2,050 | $24K | |
| 86704 | <1% | 1,996 | $24K | |
| 83021 | <1% | 1,450 | $24K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 784 | $23K |
| 87040 | <1% | 6,942 | $22K | |
| 84550 | <1% | 5,369 | $22K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 175 | $22K |
| 87481 | <1% | 605 | $21K | |
| 83615 | <1% | 3,689 | $21K | |
| 83605 | <1% | 5,575 | $21K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 575 | $21K |
| 82550 | <1% | 4,384 | $20K | |
| 86360 | <1% | 1,787 | $20K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 8,049 | $20K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,226 | $19K |
| 70486 | <1% | 157 | $18K | |
| 82077 | <1% | 2,322 | $18K | |
| 85014 | <1% | 7,230 | $17K | |
| 84132 | <1% | 3,853 | $17K | |
| 84146 | <1% | 892 | $17K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 148 | $17K |
| 82465 | <1% | 4,047 | $16K | |
| 85730 | <1% | 3,956 | $16K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 740 | $16K |
| 86359 | <1% | 1,787 | $16K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 58 | $16K |
| 82670 | <1% | 499 | $15K | |
| 84134 | <1% | 1,065 | $15K | |
| 87210 | <1% | 3,822 | $15K | |
| 85379 | <1% | 2,847 | $14K | |
| 93880 | <1% | 12 | $14K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 546 | $14K |
| 85018 | <1% | 5,038 | $13K | |
| 86765 | <1% | 1,024 | $13K | |
| 87449 | <1% | 1,066 | $13K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 4,820 | $13K |
| 83001 | <1% | 687 | $12K | |
| 82950 | <1% | 3,016 | $12K | |
| 86225 | <1% | 831 | $12K | |
| 86160 | <1% | 497 | $12K | |
| 88185 | <1% | 584 | $11K | |
| 97161 | <1% | 758 | $11K | |
| 72170 | <1% | 82 | $10K | |
| 73140 | <1% | 173 | $10K | |
| 71101 | <1% | 92 | $10K | |
| 0258 | <1% | 3,638 | $10K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 107 | $10K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 345 | $9K |
| 86003 | <1% | 298 | $9K | |
| 88341 | <1% | 48 | $8K | |
| C1769 | Guide wire | <1% | 305 | $8K |
| P9021 | Red blood cells, each unit | <1% | 147 | $8K |
| G0008 | Administration of influenza virus vaccine | <1% | 1,613 | $8K |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 130 | $8K |
| 81015 | <1% | 2,067 | $7K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,524 | $7K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,641 | $7K |
| 74022 | <1% | 165 | $7K | |
| 0370 | <1% | 1,428 | $7K | |
| 86431 | <1% | 1,100 | $7K | |
| 0710 | <1% | 771 | $7K | |
| 82977 | <1% | 980 | $6K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,031 | $6K |
| 90656 | <1% | 463 | $6K | |
| 73080 | <1% | 103 | $6K | |
| 85046 | <1% | 1,045 | $6K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,772 | $6K |
| 80179 | <1% | 709 | $6K | |
| 76870 | <1% | 70 | $6K | |
| 90662 | <1% | 486 | $5K | |
| 87205 | <1% | 2,023 | $5K | |
| 84295 | <1% | 1,116 | $5K | |
| 87324 | <1% | 474 | $5K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,695 | $5K |
| 87186 | <1% | 1,255 | $5K | |
| 70491 | <1% | 15 | $5K | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 268 | $5K |
| J1815 | Injection, insulin, per 5 units | <1% | 3,363 | $5K |
| 74170 | <1% | 14 | $5K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,948 | $4K |
| 82962 | <1% | 2,222 | $4K | |
| 86364 | <1% | 337 | $4K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,161 | $4K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,451 | $4K |
| 86300 | <1% | 190 | $4K | |
| 86769 | <1% | 173 | $4K | |
| 87522 | Neg quan hep c or qual rna | <1% | 102 | $4K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 2,418 | $4K |
| 73590 | <1% | 78 | $4K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 822 | $3K |
| 73090 | <1% | 58 | $3K | |
| 82951 | <1% | 246 | $3K | |
| 86665 | <1% | 196 | $3K | |
| 85049 | <1% | 736 | $3K | |
| 86880 | <1% | 70 | $3K | |
| 76000 | <1% | 144 | $3K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,657 | $3K |
| 84155 | <1% | 817 | $3K | |
| 86677 | <1% | 246 | $3K | |
| 82627 | <1% | 104 | $3K | |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | <1% | 231 | $3K |
| 77066 | Tomosynthesis, mammo | <1% | 14 | $2K |
| 72040 | <1% | 57 | $2K | |
| 90715 | <1% | 88 | $2K | |
| 74230 | <1% | 14 | $2K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 64 | $2K |
| 0272 | <1% | 207 | $2K | |
| 86708 | <1% | 167 | $2K | |
| 72050 | <1% | 15 | $2K | |
| 73560 | <1% | 35 | $2K | |
| 73660 | <1% | 31 | $2K | |
| 84270 | <1% | 111 | $2K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 193 | $2K |
| 96367 | <1% | 89 | $2K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 205 | $2K |
| 97116 | <1% | 241 | $2K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,750 | $2K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 12 | $2K |
| 86304 | <1% | 69 | $2K | |
| 86256 | <1% | 66 | $2K | |
| 86664 | <1% | 98 | $1K | |
| 86355 | <1% | 245 | $1K | |
| 83993 | <1% | 68 | $1K | |
| 86357 | <1% | 245 | $1K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 20 | $1K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 12 | $1K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 461 | $1K |
| 83002 | <1% | 85 | $1K | |
| 87081 | <1% | 420 | $1K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 12 | $1K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 599 | $1K |
| 87517 | <1% | 40 | $1K | |
| 80162 | <1% | 50 | $1K | |
| 82952 | <1% | 245 | $1K | |
| 80324 | <1% | 664 | $1K | |
| 80359 | <1% | 736 | $997.38 | |
| 73100 | <1% | 15 | $968.38 | |
| 83930 | <1% | 187 | $951.72 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 649 | $890.68 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 402 | $883.15 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 747 | $881.43 |
| 83935 | <1% | 168 | $845.38 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 88 | $782.75 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 576 | $776.96 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 572 | $771.94 |
| 86735 | <1% | 52 | $760.27 | |
| 87070 | <1% | 278 | $756.78 | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 64 | $756.70 |
| 87631 | <1% | 34 | $746.79 | |
| 90688 | <1% | 79 | $741.30 | |
| 86335 | <1% | 12 | $693.70 | |
| 82150 | <1% | 138 | $690.43 | |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | <1% | 413 | $679.72 |
| 88304 | <1% | 125 | $576.83 | |
| 86334 | <1% | 27 | $547.86 | |
| C1729 | Catheter, drainage | <1% | 144 | $537.59 |
| 85045 | <1% | 139 | $483.04 | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 30 | $456.77 |
| 86140 | <1% | 1,707 | $451.07 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 332 | $445.14 |
| 86308 | <1% | 90 | $429.53 | |
| 86709 | <1% | 39 | $420.65 | |
| 80164 | <1% | 39 | $391.10 | |
| 84480 | <1% | 26 | $391.00 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 227 | $368.18 |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 12 | $360.00 |
| 84145 | <1% | 90 | $338.29 | |
| 83010 | <1% | 29 | $338.00 | |
| 86039 | <1% | 40 | $307.00 | |
| 80320 | <1% | 655 | $278.40 | |
| 89051 | <1% | 94 | $251.69 | |
| 82140 | <1% | 36 | $251.65 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 89 | $248.76 |
| 85384 | <1% | 37 | $214.63 | |
| 82985 | <1% | 12 | $196.00 | |
| 82533 | <1% | 12 | $183.97 | |
| 82274 | <1% | 12 | $175.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 474 | $174.07 |
| 82330 | <1% | 13 | $159.00 | |
| J1836 | Injection, metronidazole, 10 mg | <1% | 46 | $124.88 |
| 82390 | <1% | 12 | $122.00 | |
| 88307 | <1% | 13 | $110.00 | |
| J3371 | Injection, vancomycin hcl (mylan), not therapeutically equivalent to j3370, 500 mg | <1% | 21 | $105.13 |
| 80178 | <1% | 13 | $92.00 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 26 | $88.17 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 14 | $88.15 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 15 | $76.29 |
| 82705 | <1% | 13 | $72.00 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 39 | $62.71 |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 128 | $54.18 |
| J2305 | Injection, nitroglycerin, 5 mg | <1% | 12 | $46.15 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 22 | $39.98 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 220 | $24.50 |
| V2632 | Posterior chamber intraocular lens | <1% | 195 | $15.82 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 12 | $11.15 |
| 3052F | <1% | 178 | $0.01 | |
| 3051F | <1% | 320 | $0.01 | |
| 3074F | 0% | 45 | $0.00 | |
| 80329 | 0% | 424 | $0.00 | |
| 3044F | 0% | 3,303 | $0.00 | |
| 3046F | 0% | 284 | $0.00 | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | 0% | 49 | $0.00 |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 13 | $0.00 |
| 3078F | 0% | 40 | $0.00 | |
| J0694 | Injection, cefoxitin sodium, 1 gm | 0% | 13 | $0.00 |
| C1757 | Catheter, thrombectomy/embolectomy | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGRICE, WILLIAM (EXECUTIVE DIRECTOR)
| Provider | Location | Paid |
|---|---|---|
| Kaiser Foundation Hospitals | Los Angeles, CA | $27.41M |
| Kaiser Foundation Hospitals | Pasadena, CA | $6.60M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.